CRISPR Therapeutics AG (NASDAQ:CRSP) - Investment analysts at Piper Sandler decreased their Q1 2021 EPS estimates for CRISPR Therapeutics in a report issued on Tuesday, February 16th. Piper Sandler analyst E. Tenthoff now expects that the company will earn ($1.46) per share for the quarter, down from their prior forecast of ($1.44). Piper Sandler has a "Overweight" rating and a $180.00 price objective on the stock. Piper Sandler also issued estimates for CRISPR Therapeutics' Q3 2021 earnings at ($1.61) EPS, Q4 2021 earnings at ($1.77) EPS, FY2021 earnings at ($6.40) EPS, Q1 2022 earnings at ($1.83) EPS, Q2 2022 earnings at ($1.96) EPS, Q3 2022 earnings at ($1.98) EPS, Q4 2022 earnings at ($1.97) EPS and FY2022 earnings at ($7.74) EPS.
A number of other research analysts also recently commented on CRSP. Zacks Investment Research downgraded CRISPR Therapeutics from a "hold" rating to a "sell" rating and set a $177.00 target price on the stock. in a report on Monday, February 1st. Canaccord Genuity raised their price target on CRISPR Therapeutics from $120.00 to $151.00 and gave the stock a "buy" rating in a report on Monday, December 7th. Raymond James reissued a "sell" rating on shares of CRISPR Therapeutics in a report on Friday, October 30th. Truist raised their price target on CRISPR Therapeutics from $170.00 to $210.00 in a report on Tuesday, January 12th. Finally, Wells Fargo & Company downgraded CRISPR Therapeutics from an "overweight" rating to an "equal weight" rating and raised their price target for the stock from $102.63 to $145.00 in a report on Monday, December 7th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of "Hold" and a consensus target price of $149.50.
Shares of NASDAQ CRSP opened at $148.98 on Friday. CRISPR Therapeutics has a fifty-two week low of $32.30 and a fifty-two week high of $220.20. The business has a 50 day moving average price of $174.64 and a two-hundred day moving average price of $123.49. The firm has a market cap of $11.24 billion, a PE ratio of -45.70 and a beta of 2.37. CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, February 15th. The company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.23). CRISPR Therapeutics had a negative net margin of 273.10% and a negative return on equity of 20.72%.
In other news, President Rodger Novak sold 100,000 shares of CRISPR Therapeutics stock in a transaction on Monday, November 30th. The stock was sold at an average price of $125.00, for a total transaction of $12,500,000.00. Following the transaction, the president now directly owns 698,007 shares in the company, valued at approximately $87,250,875. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Bradley J. Phd Bolzon sold 171,004 shares of CRISPR Therapeutics stock in a transaction on Monday, December 7th. The shares were sold at an average price of $154.53, for a total value of $26,425,248.12. Following the transaction, the director now owns 40,648 shares in the company, valued at $6,281,335.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 427,703 shares of company stock worth $66,444,533. 17.10% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Webster Bank N. A. acquired a new position in shares of CRISPR Therapeutics in the 3rd quarter worth $27,000. Trustcore Financial Services LLC acquired a new position in shares of CRISPR Therapeutics in the 4th quarter worth $31,000. Summit X LLC acquired a new position in shares of CRISPR Therapeutics in the 3rd quarter worth $34,000. Parallel Advisors LLC acquired a new position in shares of CRISPR Therapeutics in the 4th quarter worth $38,000. Finally, Capital Advisory Group Advisory Services LLC grew its holdings in shares of CRISPR Therapeutics by 300.0% in the 4th quarter. Capital Advisory Group Advisory Services LLC now owns 248 shares of the company's stock worth $38,000 after acquiring an additional 186 shares during the last quarter. Institutional investors and hedge funds own 66.43% of the company's stock.
About CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Further Reading: What are the benefits of investing in REITs?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]